Radius Health (RDUS) Tops Q4 EPS by 51c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
February 28, 2019 4:06 PM ESTTYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Companys guidance of $95-98 million.
Elacestrants Phase 3 study was initiated at the end of 2018 and is open for enrollment.
Radius maintains its financial guidance for 2019 with full-year TYMLOS U.S. net sales expected to be between $155 to $175 million and year-end cash, cash equivalents & investments expected to exceed $100 million.
Conference call scheduled for 4:30 p.m. ET today... More
